Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S ADR
(NY:
NVO
)
134.89
-2.17 (-1.58%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novo Nordisk A/S ADR
< Previous
1
2
3
4
5
6
7
8
9
...
57
58
Next >
Is Eli Lilly a Good Dividend Stock to Buy Now?
July 14, 2024
A leading anti-obesity treatment plus a new Alzheimer's drug could drive profits through the roof.
Via
The Motley Fool
This 1 Piece of Bad News for Novo Nordisk Is Good News for Eli Lilly Stock
July 14, 2024
A new study raises important implications regarding the competitive balance between these two companies.
Via
The Motley Fool
Here's 80 Billion More Reasons to Buy Novo Nordisk Stock
July 13, 2024
Hopes are high about one of its next-gen candidates.
Via
The Motley Fool
The 7 Most Important Stocks to Watch as Q2 Earnings Season Kicks Off
July 13, 2024
Seven Q2 earnings season stocks are powered by catalysts that could have a major impact on their companies fortunes.
Via
InvestorPlace
Did Eli Lilly Just Get a Leg Up on Novo Nordisk?
July 13, 2024
Eli Lilly's latest milestone sets it apart from its rival Novo Nordisk.
Via
The Motley Fool
Will NVO Provide Any Buying Opportunity?
July 08, 2024
Novo Nordisk A/S, a healthcare company engages in the research, development, manufacture & marketing of the pharmaceutical products worldwide.
Via
Talk Markets
The Weight Loss Market Can Surge To $400B By 2032, And These Stocks Will Rule It
July 12, 2024
Despite Novo Nordisk's momentum, Eli Lilly seems a better long-term bet. Pfizer could surprise everyone from an undervalued position.
Via
Talk Markets
Novo Nordisk Stock Pops After Weight-Loss Drug Cuts Dementia Risk In Yearlong Study
July 12, 2024
A yearlong study at the University of Oxford suggests GLP-1 drugs could play a role in protecting brain health.
Via
Investor's Business Daily
Stock Market Shifts Toward Small Caps After Tame CPI; JPMorgan, Taiwan Semi, Tesla In Focus: Weekly Review
July 12, 2024
Megacaps and chip plays tumbled Thursday, but mostly still have healthy charts.
Via
Investor's Business Daily
Using Ozempic, Zepbound Or Other Weight Loss Drugs? Inform Doctors Before Anesthesia Or Surgery, European Medicines Agency Issues Advisory
July 12, 2024
EMA advises patients on GLP-1 weight-loss drugs like Wegovy to inform their doctors before surgery due to potential respiratory risks. New warnings to be included in product information to ensure...
Via
Benzinga
3 Global Stocks Worth Buying as America Stumbles
July 12, 2024
It never hurts to diversify your portfolio by adding global stocks, even if America doesn’t fall into the abyss.
Via
InvestorPlace
The 3 Most Undervalued Pharma Stocks to Buy in July 2024
July 12, 2024
Pharma stocks can be great investments during times of growth and recession, and are made even better if the stock is undervalued.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
Novo Nordisk's 'Miracle' Weight Loss Drug Ozempic Linked To 48% Lower Risk Of Dementia, Study Finds
July 12, 2024
Novo Nordisk has found that its diabetes drug, Ozempic, is linked to a significant reduction in the risk of dementia and other cognitive issues.
Via
Benzinga
Eli Lilly, Novo Nordisk Shares Dip As Pfizer Ramps Up Diabetes Drug Competition
July 11, 2024
Shares of Eli Lilly and Co (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) are facing declines Thursday, maybe influenced by competitive developments and regulatory updates in the pharmaceutical sector.
Via
Benzinga
Bernie Sanders Targets High Prices of Ozempic and Wegovy In US
July 11, 2024
Senator Bernie Sanders is pushing Novo Nordisk to lower U.S. prices for weight-loss drugs Ozempic and Wegovy, as part of a broader effort to reduce drug costs and expand Medicare price negotiations.
Via
Benzinga
FDA Rejects Novo Nordisk's Weekly Insulin, Requests Information Related To Manufacturing Process, Type 1 Diabetes
July 11, 2024
The FDA has issued a Complete Response Letter to Novo Nordisk's Biologics License Application for once-weekly basal insulin icodec. Novo Nordisk aims to address the FDA's requests but anticipates...
Via
Benzinga
Exposures
Product Safety
EXCLUSIVE: Vivani Medical Outlines Plans To Kickstart First Clinical Study For Miniature GLP-1 Obesity Implant Program This Year
July 11, 2024
Vivani Medical plans to start the first clinical study of the NPM-115 program in Australia in Q4 2024. The study will evaluate a 6-month GLP-1 implant for chronic weight management in obese or...
Via
Benzinga
Chipotle Just Did a Stock Split. History Says This Is What Might Happen Next.
July 11, 2024
Big-name stocks that have split their shares in recent years have generally done fairly well afterward.
Via
The Motley Fool
Jim Cramer Identifies Eight Companies Eyeing Trillion-Dollar Club — Elon Musk's Tesla, Eli Lilly Top Contenders
July 11, 2024
Jim Cramer has identified eight companies that could potentially reach a market cap of $1 trillion, including Elon Musk's Tesla, and Eli Lilly.
Via
Benzinga
3 Pharma Stocks That Could Make Your Grandchildren Rich
July 10, 2024
Investors might want to consider the top pharma stocks in the current environment as they are beating most others.
Via
InvestorPlace
Only 25% Patients Stick With Novo Nordisk's Wegovy Or Ozempic After 2 Years, A Study Shows; Company Calls Data Insufficient
July 10, 2024
A study shows that only one in four U.S. patients prescribed Novo Nordisk's weight-loss drugs Wegovy or Ozempic remain on the medication after two years, raising concerns about long-term adherence.
Via
Benzinga
Stay Away: Why Ginkgo Bioworks Stock Is Not for the Faint-Hearted
July 10, 2024
Ginkgo Bioworks stock is down, but this doesn't mean it's a bargain as Ginkgo Bioworks faces a serious delisting threat.
Via
InvestorPlace
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
July 09, 2024
Global pharmaceutical company Eli Lilly & Co. (NYSE: LLY) has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been
Via
MarketBeat
7 Bullish Stock Picks With the Potential to Turn $5K Into $50K
July 09, 2024
These high-potential stock picks each have 10X potential moving forward and are well worth understanding despite high prices in some cases.
Via
InvestorPlace
3 Stocks With the Potential to 10X Your Money
July 09, 2024
These three top high-growth potential stocks could offer substantial growth and give your portfolio a major boost.
Via
InvestorPlace
Eli Lilly Rose More Than 50% So Far This Year. Can It Soar Past $1,000 in the 2nd Half?
July 09, 2024
This pharma company is posting double-digit revenue growth.
Via
The Motley Fool
Eli Lilly's Mounjaro Outpaces Novo Nordisk's Ozempic In Weight Loss Effectiveness, Study Shows
July 09, 2024
Eli Lilly and Co has emerged victorious in the weight loss drug competition, in a recent study. The study found that patients on Lilly's Mounjaro lost more weight than those on Novo Nordisk's Ozempic.
Via
Benzinga
Patients Lost More Weight On Eli Lilly's Mounjaro Than Novo Nordisk's Ozempic
July 08, 2024
Patients lost more more weight on Mounjaro than Ozempic.
Via
Investor's Business Daily
3 Overlooked Giants-in-the-Making for Patient Investors
July 08, 2024
Consider buying into these overlooked growth stocks for long-term profits that will help to boost a portfolio and deliver riches.
Via
InvestorPlace
Novartis Stock Generating Improved Relative Strength
July 08, 2024
Top and bottom line growth moved higher in Novartis' most recent quarter. EPS rose 17% to $1.80. Revenue increased 10% to $12.1 billion.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
...
57
58
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.